NIFTY 50

Will support others instead of launching COVID-19 vaccine programmes: Novartis AG

Updated : February 25, 2021 06:11 PM IST

Almost six years after Novartis AG sold off its vaccine division to rival GSK, the Swiss drug major is assessing its way back into the vaccine space, however differently this time.

CNBC-TV18’s Archana Shukla caught up with Lutz Hegemann, Group Head-Corporate Affairs of the pharma company at BioAsia 2021, and asked if there is any re-entry at the vaccine front.

“To an extent yes, but not that we would reactivate our former vaccine division because we would subscale and not competitive if we do not have all the resources at our end. Therefore, we are not looking to launch competitive COVID vaccine programmes," he said.

“When you have 5-10-20 vaccine candidates, I think it is more important that you focus on a few and help to accelerate those who want to increase manufacturing capacity. I believe it's more of a service to mankind than trying to have competing research programmes that potentially maybe subscale or may not get you to the desired outcome,” he said.

For more details, watch the video.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you